Literature DB >> 7947378

Cardioselectivity of calcium antagonists.

T Godfraind1.   

Abstract

Calcium antagonists comprise a diverse group of chemically unrelated agents that interact with voltage-operated calcium channels (L-type) and thereby inhibit smooth muscle and cardiac contractility. Although they interact with the alpha 1 subunit of voltage-operated calcium channels, all calcium antagonists are not identical pharmacological agents. They are not only different from a chemical point of view, but also because some of them exhibit tissue selectivity, being more powerful blockers of the contraction of arteries than of cardiac muscle. The current view that their major therapeutic action is related to vasodilation is an oversimplification, as their action is more complex and may be related to factors other than hemodynamic ones.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7947378     DOI: 10.1007/bf00877320

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  62 in total

Review 1.  Distribution and functional significance of the P-type, voltage-dependent Ca2+ channels in the mammalian central nervous system.

Authors:  R Llinás; M Sugimori; D E Hillman; B Cherksey
Journal:  Trends Neurosci       Date:  1992-09       Impact factor: 13.837

2.  Calcium antagonist caution.

Authors: 
Journal:  Lancet       Date:  1991-04-13       Impact factor: 79.321

Review 3.  Physiopathology of neuronal voltage-operated calcium channels.

Authors:  E Sher; E Biancardi; M Passafaro; F Clementi
Journal:  FASEB J       Date:  1991-09       Impact factor: 5.191

4.  The positive inotropic action of the nifedipine analogue, Bay K 8644, in guinea-pig and rat isolated cardiac preparations.

Authors:  M Finet; T Godfraind; G Khoury
Journal:  Br J Pharmacol       Date:  1985-09       Impact factor: 8.739

Review 5.  Calcium antagonists. History and perspective.

Authors:  D J Triggle
Journal:  Stroke       Date:  1990-12       Impact factor: 7.914

6.  Cardiac contractility and sarcolemmal calcium binding in several cardiac muscle preparations.

Authors:  D M Bers; K D Philipson; G A Langer
Journal:  Am J Physiol       Date:  1981-04

Review 7.  How should physicians view heart failure? The philosophical and physiological evolution of three conceptual models of the disease.

Authors:  M Packer
Journal:  Am J Cardiol       Date:  1993-03-25       Impact factor: 2.778

8.  Acute and chronic effects of the dihydropyridine calcium antagonist nisoldipine on the resting and exercise hemodynamics, neurohumoral parameters, and functional capacity of patients with chronic heart failure.

Authors:  L Dei Cas; M Metra; R Ferrari; O Visioli
Journal:  Cardiovasc Drugs Ther       Date:  1993-02       Impact factor: 3.727

9.  Expression of dihydropyridine receptor (Ca2+ channel) and calsequestrin genes in the myocardium of patients with end-stage heart failure.

Authors:  T Takahashi; P D Allen; R V Lacro; A R Marks; A R Dennis; F J Schoen; W Grossman; J D Marsh; S Izumo
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

10.  Calcium channel selectivity for divalent and monovalent cations. Voltage and concentration dependence of single channel current in ventricular heart cells.

Authors:  P Hess; J B Lansman; R W Tsien
Journal:  J Gen Physiol       Date:  1986-09       Impact factor: 4.086

View more
  3 in total

Review 1.  How do calcium channel blockers prevent cardiovascular events. Are they all alike?

Authors:  M G Bogaert
Journal:  Drugs       Date:  1996       Impact factor: 9.546

Review 2.  Nisoldipine coat-core. A review of its pharmacology and therapeutic efficacy in hypertension.

Authors:  G L Plosker; D Faulds
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

Review 3.  Vascular selective calcium entry blockers in the treatment of cardiovascular disorders: focus on felodipine.

Authors:  W C Little; C P Cheng; L Elvelin; M Nordlander
Journal:  Cardiovasc Drugs Ther       Date:  1995-10       Impact factor: 3.727

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.